Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Basilea Pharmaceutica AG, commonly referred to as Basilea, is a Swiss biopharmaceutical company headquartered in Basel, Switzerland. Founded in 2000, Basilea focuses on the development and commercialisation of innovative therapies for oncology and infectious diseases. The company has made significant strides in the pharmaceutical industry, particularly with its core products, which include advanced treatments for resistant infections and cancer.
Basilea's unique approach combines cutting-edge research with a commitment to addressing unmet medical needs, positioning it as a key player in the global biopharmaceutical landscape. With a strong presence in Europe and North America, Basilea has achieved notable milestones, including successful product launches and strategic partnerships that enhance its market position. The company's dedication to innovation and patient care continues to drive its growth and reputation in the industry.
-19 vs industry average
Basilea Pharmaceutica’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2024, Basilea Pharmaceutica reported Scope 2 emissions of approximately 19,800 kg CO2e (market-based) and 130,700 kg CO2e (location-based). For the previous year, 2023, the company recorded Scope 2 emissions of about 18,800 kg CO2e (market-based) and 121,200 kg CO2e (location-based). Notably, Basilea Pharmaceutica does not currently disclose Scope 1 or Scope 3 emissions data.
Despite the absence of specific reduction targets or initiatives, the company is committed to improving its environmental impact. However, no formal climate pledges or SBTi (Science Based Targets initiative) targets have been established. As a result, Basilea Pharmaceutica's climate commitments remain somewhat undefined within the context of industry standards.
The emissions data is not cascaded from any parent organization, indicating that Basilea Pharmaceutica AG operates independently in its reporting and climate strategy.
No climate goals have been disclosed for Basilea Pharmaceutica yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more